Active Ingredient History

  • Now
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix. Its development has been discontinued.   Wikipedia

More Chemistry
dusigitumab | medi-573


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue